06
May
2024

Lowey Dannenberg, P.C. Ranked #1 Law Firm Based on Antitrust Settlements

Lowey Dannenberg P.C. is proud to announce that the firm has been included in this year’s ISS Securities Class Action Services (“ISS SCAS”) Top Plaintiff Law Firms of 2023 report, as the Firm was ranked #1 Law Firm based on Antitrust Settlements. The Firm topped the list with $224.45 million in total settlement funds across five partial settlements, including: the…
Read More
Securities

24
April
2024

Global Cord Blood Corporation

A securities class action has been filed in the USDC – S.D.N.Y. against Global Cord Blood Corporation (CORBF) ("Global Cord" or the "Company"), on behalf of all persons and entities that purchased or otherwise acquired Global Cord securities between June 4, 2019 and May 3, 2022, both dates inclusive (the “Class Period”). Global Cord, together with its subsidiaries, provides umbilical…
Read More
Securities

03
January
2024

Consumer Alert: Lowey Dannenberg, P.C., Investigates Claims Against Toyota Motor Corporation

NEW YORK, Jan. 3, 2023 – Lowey Dannenberg P.C. is investigating consumer claims for potential violation of consumer protection statutes by Toyota Motor Corporation (“Toyota” or the “Company”). If you purchased a vehicle from Lexus (Toyota’s subsidiary) or Toyota, the automaker of the Prius, Camry, Highlander, Corolla, etc., after November 14, 2022, please contact Lowey Dannenberg at (914)-733-7272 or via…
Read More

19
December
2023

Lowey Dannenberg and Co-Counsel File Class Action on Behalf of End-Payors for Immunosuppressive Drug Stelara (Ustekinumab)

On December 7, 2023, Lowey Dannenberg, P.C. and its co-counsel, representing named Plaintiff CareFirst BlueCross BlueShield,filed suit against Stelara manufacturer Johnson & Johnson (“J&J”) in the U.S. District Court for the Eastern District of Virginia. The Complaint alleges that J&J is engaged in an ongoing scheme to delay the entry of biosimilar competition for Stelara, thereby monopolizing the lucrative market…
Read More